Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.

Immunosenescence denotes the gradual decline of immune competence with age. Thymic involution, mitochondrial dysfunction in T cells, and chronic low-grade inflammation are central features. A 2021 paper in Biochemistry (Moscow) reported that the peptide Cortagen (Ala-Glu-Asp-Pro) partially restored thymic architecture in aged rats. Separately, NAD+ precursors have been investigated for their capacity to improve mitochondrial respiration in human lymphocytes. The question is whether these two interventions, when combined, address distinct nodes of immune aging.

What Immunosenescence Actually Involves

Immunosenescence is not a single event. It includes reduced output of naive T cells, accumulation of exhausted memory cells, and a shift toward pro-inflammatory cytokine secretion. The thymus, which produces new T cells, begins to shrink after puberty. By age 70, functional thymic tissue is often replaced by fat. A 2019 review in Frontiers in Immunology described how mitochondrial dysfunction in aged T cells limits their metabolic flexibility. Without adequate NAD+, T cells cannot efficiently perform oxidative phosphorylation or glycolysis upon activation.

This is where NAD+ becomes relevant. NAD+ is a coenzyme for sirtuins and PARPs, both of which regulate immune cell function. A 2022 study (PubMed) reported that boosting NAD+ in aged mice improved T cell mitochondrial mass and reduced markers of senescence. However, NAD+ alone does not rebuild thymic tissue. That requires a different signal.

Cortagen and the Thymic Microenvironment

Cortagen is a synthetic tetrapeptide originally developed in Russia. Its sequence is Ala-Glu-Asp-Pro. In a 2020 trial published in Advances in Gerontology, Cortagen administration in elderly patients was associated with increased CD3+ lymphocyte counts. The same group had earlier shown that Cortagen stimulated thymic epithelial cell proliferation in vitro. A 2021 paper in Bulletin of Experimental Biology and Medicine reported that Cortagen reduced thymocyte apoptosis in aged rats. These findings suggest Cortagen acts on the thymic stroma, not directly on T cells.

For a broader look at NAD+ and Cortagen for cognitive longevity, see this analysis of the brain-focused stack. The mechanism there is different, involving neurotrophic factors. But the principle is similar: one molecule supports energy metabolism, the other supports tissue-specific regeneration.

Mitochondrial Rejuvenation via NAD+

NAD+ levels decline with age in multiple tissues, including immune cells. This decline impairs sirtuin activity, particularly SIRT1 and SIRT3. SIRT3 is mitochondrial and regulates enzymes like isocitrate dehydrogenase and superoxide dismutase. A 2018 study in Cell Metabolism showed that restoring NAD+ in old mice improved mitochondrial function in muscle stem cells. Similar logic applies to T cells.

But NAD+ precursors have limitations. They do not address thymic involution. They do not directly reduce the burden of cytomegalovirus-driven T cell clonal expansion, a major driver of immunosenescence in humans. For a discussion of NAD+ infusions and immunosenescence, see this review of infusion protocols. The evidence there is mixed, with some studies showing improved markers and others showing no change in vaccine response.

Why a Stack Might Work Better Than Either Alone

The rationale for combining NAD+ and Cortagen is based on two non-overlapping mechanisms. NAD+ addresses the metabolic capacity of existing T cells. Cortagen addresses the supply of new T cells from the thymus. In theory, improving both could yield a more functional immune system than improving either alone.

A 2022 review in International Journal of Molecular Sciences proposed that mitochondrial rejuvenation and thymic regeneration are complementary strategies for immunosenescence. The authors noted that no single intervention has succeeded in reversing immune aging in humans. They suggested that combination approaches, including peptides and metabolic precursors, deserve further study.

For a related stack involving GHK-Cu, which also targets cellular senescence, see this article on GHK-Cu and NAD+ for senescent cell clearance. GHK-Cu has different effects on copper-dependent enzymes and extracellular matrix remodeling. It is not a thymic peptide, but it shares the goal of reducing senescent cell burden.

What Animal and In Vitro Data Actually Show

Most data on Cortagen come from Russian laboratories. A 2019 study in Advances in Gerontology reported that Cortagen increased thymic index in aged rats by 22% after 10 days of administration. Thymic index is a crude measure, typically thymus weight relative to body weight. It does not prove functional improvement. However, the same study found increased numbers of CD4+CD8+ double-positive thymocytes, suggesting enhanced thymopoiesis.

NAD+ data are more extensive but also more heterogeneous. A 2021 trial in Nature Aging tested nicotinamide riboside in older adults. The trial found increased NAD+ levels in blood but no significant change in immune cell subsets. A smaller 2020 study reported improved respiratory capacity in peripheral blood mononuclear cells after 6 weeks of nicotinamide mononucleotide. The discrepancy may reflect differences in dose, duration, or baseline NAD+ status.

No published study has tested NAD+ and Cortagen together in humans. The stack is theoretical. It is based on mechanistic plausibility, not clinical evidence.

Potential Risks and Unknowns

NAD+ precursors are generally well tolerated at moderate doses. Common side effects include nausea, flushing, and headache. Long-term safety data are limited. Cortagen has been used in Russia for decades, but Western regulatory agencies have not evaluated it. Its safety profile is based on observational data and small trials.

One concern is that boosting NAD+ might fuel the growth of certain cancers. NAD+ is required for rapid cell division. A 2019 paper in Nature Cell Biology showed that cancer cells can use NAD+ salvage pathways to support proliferation. Whether NAD+ precursors increase cancer risk in humans is unknown. This is a reason for caution, especially in older adults with undiagnosed malignancies.

Cortagen, as a peptide, may have immunogenic potential. Repeated administration could theoretically trigger antibody formation. No such antibodies have been reported in published studies, but the possibility exists. Peptide stability and purity are also concerns when sourcing from non-pharmaceutical suppliers.

Where the Evidence Ends

The hypothesis that NAD+ and Cortagen can reverse immunosenescence is not supported by human trial data. It is supported by separate lines of animal and in vitro work. NAD+ improves mitochondrial function in aged T cells. Cortagen improves thymic architecture in aged rodents. Whether these effects translate to humans, and whether they are additive, is unknown.

A 2023 review in Ageing Research Reviews concluded that immunosenescence is multifactorial and unlikely to be reversed by any single agent. The authors emphasized the need for combination strategies targeting both cell-intrinsic and cell-extrinsic mechanisms. NAD+ and Cortagen fit that framework, but they are not the only candidates. Epitalon, for example, has been studied for its effects on pineal function and circadian rhythms, which also influence immune aging. See this analysis of NAD+ and Epitalon for a different combination.

Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.